Advertisement

BioDrugs

, Volume 21, Issue 4, pp 259–267 | Cite as

Biotechnology and the Treatment of Addictive Disorders

  • Ahmed Elkashef
  • Jamie Biswas
  • Jane B. Acri
  • Frank Vocci
Novel Therapeutic Strategies

Abstract

Addiction is a chronic relapsing illness with onset typically occurring in the early teenage years, followed by cycles of drug use and abstinence. The disease is mitigated by complex interactions between genes and environment. Viewed as such, the treatment of addiction could span the whole lifetime of the patient and, ideally, should be tailored to the illness cycle. The search for effective treatments has intensified recently due to our better understanding of the underlying neurobiologic mechanisms contributing to drug use and relapse. The three main types of treatment are behavioral, pharmacologic and, more recently, immunologic therapies. Vaccines and monoclonal antibodies are being developed mainly for stimulant use disorders and nicotine addiction. In addition, new molecular targets identified by preclinical research have shown promise and are awaiting proof-of-concept studies in humans. The main focus of this review is on the development of immunotherapy for stimulants and nicotine addiction as a model highlighting the current status of the science and potential emerging discoveries and development.

Keywords

Nicotine Cocaine Methamphetamine Modafinil Varenicline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Merikangas KR, Stolar M, Stevens DE, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55: 973–9PubMedCrossRefGoogle Scholar
  2. 2.
    Bierut LJ, Dinwiddie SH, Begleiter H, et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking. A report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry 1998; 55: 982–8PubMedCrossRefGoogle Scholar
  3. 3.
    Langbehn DR, Cadoret RJ, Caspers K, et al. Genetic and environmental risk factors for the onset of drug use and problems in adoptees. Drug Alcohol Depend 2003; 69: 151–67PubMedCrossRefGoogle Scholar
  4. 4.
    Kendler KS, Prescott CA, Myers J, et al. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60: 929–37PubMedCrossRefGoogle Scholar
  5. 5.
    Chassin L, Pitts SC, Prost J. Binge drinking trajectories from adolescence to emerging adulthood in a high-risk sample: predictors and substance abuse outcomes. J Consult Clin Psychol 2002; 70: 67–78PubMedCrossRefGoogle Scholar
  6. 6.
    Kreek MJ, Bart G, Lilly C, et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005; 57: 1–26PubMedCrossRefGoogle Scholar
  7. 7.
    Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implication for substance abuse prevention. Psychol Bull 1992; 112: 64–105PubMedCrossRefGoogle Scholar
  8. 8.
    Bry BH, McKeon P, Pandina RJ. Extent of drug use as a function of number of risk factors. J Abnorm Psychol 1982; 91: 273–9PubMedCrossRefGoogle Scholar
  9. 9.
    Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159: 1642–52PubMedCrossRefGoogle Scholar
  10. 10.
    Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001; 2: 695–703PubMedCrossRefGoogle Scholar
  11. 11.
    Nestler EJ. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 2002; 78: 637–47PubMedCrossRefGoogle Scholar
  12. 12.
    Chao J, Nestler EJ. Molecular neurobiology of drug addiction. Annu Rev Med 2004; 55: 113–32PubMedCrossRefGoogle Scholar
  13. 13.
    Kelley AE. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004; 44: 161–79PubMedCrossRefGoogle Scholar
  14. 14.
    Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neurop-sychopharmology 1996; 14: 375–424CrossRefGoogle Scholar
  15. 15.
    O’Brien CP, Gardner EL. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 2005 Oct; 161(10): 18–58CrossRefGoogle Scholar
  16. 16.
    Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results from imaging in studies and treatment implications. Mol Psychiatry 2004 Jun; 9(6): 557–69PubMedCrossRefGoogle Scholar
  17. 17.
    Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001 Dec; 158(12): 2015–1021PubMedCrossRefGoogle Scholar
  18. 18.
    Brody AL, Mandelkern MA, Olmstead RE, et al. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 2006 Jul; 63: 808–16PubMedCrossRefGoogle Scholar
  19. 19.
    Staley JK, Krishnan-Sarin S, Cosgrove KP, et al. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci 2006 Aug; 26(34): 8707–14PubMedCrossRefGoogle Scholar
  20. 20.
    United Nations Office on Drugs and Crime. Global illicit drug trends: 2003. New York: United Nations Publication, 2003 [online]. Available from URL: http://www.unodc.org/pdf/trends2003_www_E.pdf [Accessed 2007 Jun 25]
  21. 21.
    Substance Abuse and Mental Health Services Administration. Results from the 2004 national survey on drug use and health findings. NSDUH Series H-28 [DHHS Publication No. SMA 05-4062]. Rockville (MD): Office of Applied Studies, 2005Google Scholar
  22. 22.
    da Costa e Silva V, editor. Tools for advancing tobacco control in the XXIst century: Policy recommendations for smoking cessation and treatment of tobacco dependence — tools for public health. Geneva: World Health Organization, 2003 [online]. Available from URL: http://www.who.int/tobacco/resources/publications/en/intro_chapter3.pdf [Accessed 2007 Jun 25]Google Scholar
  23. 23.
    United Nations Office for Drug Control and Crime Prevention (UNODCCP). ODCCP studies on drugs and crime control: global illicit drug trends 2002. New York: United Nations Publications, 2002Google Scholar
  24. 24.
    United Nations Office on Drugs and Crime (UNODC). Ecstasy and amphetamines, global survey. New York: United Nations Publications, 2003Google Scholar
  25. 25.
    World Health Organization. Tobacco free initiative 2006 [online]. Available from URL: http://www.who.int/tobacco/health_priority/en/index.html [Accessed 2007 Jun 6]
  26. 26.
    American Lung Association, Epidemiology and Statistics Unit Research and Program Services. Trends in tobacco use: 2006. New York: American Lung Association, 2006Google Scholar
  27. 27.
    Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trials. Arch Gen Psychiatry 2004 Mar; 61(3): 264–72PubMedCrossRefGoogle Scholar
  28. 28.
    Kackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005 Jan; 30(1): 205–11CrossRefGoogle Scholar
  29. 29.
    Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004 Sep; 75(3): 233–40PubMedCrossRefGoogle Scholar
  30. 30.
    Elkashef AM, Rawson RA, Smith E, et al. Bupropion for the treatment of methamphetamine dependence [abstract]. Scottsdale (AZ): College on Problems of Drug Dependence, 2006: 215Google Scholar
  31. 31.
    Herman B, Elkashef A, Vocci F. Medications for the treatment of cocaine addiction: emerging candidates. Drug Discov Today Ther Strat 2005; 2(1): 87–92CrossRefGoogle Scholar
  32. 32.
    Dewey SL, Chaurasia CS, Chen CE, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 1997; 25(4): 393–8PubMedCrossRefGoogle Scholar
  33. 33.
    Koob GF. Stress, corticotrophin-releasing factor, and drug addiction. Ann NY Acad Sci 1999; 897: 27–45PubMedCrossRefGoogle Scholar
  34. 34.
    Stewart J. Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci 2000; 25(2): 125–36PubMedGoogle Scholar
  35. 35.
    Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001; 53(2): 209–43PubMedGoogle Scholar
  36. 36.
    Erb S, Shaham Y, Stewart J. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neuroscience 1998; 18(4): 4429–5536Google Scholar
  37. 37.
    Shaham Y, Erb S, Leung S, et al. CP-154-526, a selective, non-peptide antagonist of the corticotropin-releasing factorl receptor attenuates stress-induced relapse to drug seeking cocaine- and heroin-trained rates. Psychopharmacology (Berl) 1998; 137(2): 184–90PubMedCrossRefGoogle Scholar
  38. 38.
    Shaham Y, Funk D, Erb S, et al. Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 1997; 17(7): 2605–14PubMedGoogle Scholar
  39. 39.
    Le AD, Harding S, Juzytsch W, et al. The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 2000; 150(3): 317–24CrossRefGoogle Scholar
  40. 40.
    Sokoloff P, Le FB, Perachon S, et al. The dopamine D3 receptor and drug addiction. Neurotox Res 2001; 3(5): 433–41PubMedCrossRefGoogle Scholar
  41. 41.
    Heidbreder CA, Gardner EL, Xi ZX, et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 2005; 49(1): 77–105PubMedCrossRefGoogle Scholar
  42. 42.
    Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005; 10(13): 917–25PubMedCrossRefGoogle Scholar
  43. 43.
    Newman AH, Grundt P, Nader MA. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 2005; 48(11): 3663–79PubMedCrossRefGoogle Scholar
  44. 44.
    Andreoli M, Tessari M, Pilla M, et al. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003; 28(7): 1272–80PubMedCrossRefGoogle Scholar
  45. 45.
    Di Ciano P, Underwood RJ, Hagan JJ, et al. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003; 28(2): 329–38CrossRefGoogle Scholar
  46. 46.
    Gilbert JG, Newman AH, Gardner EL, et al. Acute administration of SB-277011 A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005; 57(1): 17–28PubMedCrossRefGoogle Scholar
  47. 47.
    Xi ZX, Gilbert J, Campos AC, et al. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking rats. Psychopharmacology (Berl) 2004; 176(1): 57–65CrossRefGoogle Scholar
  48. 48.
    Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005; 312(3): 875–83Google Scholar
  49. 49.
    Beardsley PM, Thomas BF. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol 2005; 16(5-6): 275–96PubMedCrossRefGoogle Scholar
  50. 50.
    Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003; 8(4): 373–82PubMedCrossRefGoogle Scholar
  51. 51.
    Fagerström K, Balfour DJ. Neuropharmacology and potential efficacy of new treatment for tobacco dependence. Expert Opin Investig Drugs 2005; 15(2): 107–16CrossRefGoogle Scholar
  52. 52.
    Foulds J, Steinberg MB, William JM, et al. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev 2006; 25: 59–71PubMedCrossRefGoogle Scholar
  53. 53.
    Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20: 1196–204PubMedCrossRefGoogle Scholar
  54. 54.
    Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58: 158–64PubMedCrossRefGoogle Scholar
  55. 55.
    Preliminary results of phase 2 clinical trials with TA-CD, cocaine addiction vaccine. Celtic Pharma 2006 Jun 21 [online]. Available from URL: http://www.celticpharma.com/news/ [Accessed 2007 Jun 25]
  56. 56.
    Fox BS, Kantak KM, Edwards MA, et al. Efficacy of therapeutic cocaine vaccine in rodent models. Nat Med 1996 Oct; 2(10): 1073–4CrossRefGoogle Scholar
  57. 57.
    Carrera MRA, Trigo JM, Wirsching P, et al. Evaluation of the anticocaine nomoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 2005; 81: 709–14PubMedCrossRefGoogle Scholar
  58. 58.
    Byrnes-Blake KA, Carroll FI, Abraham P, et al. Generation of aniti-(+) methamphetamine antibodies is not impeded by (+) methamphetamine administration during active immunization of rats. Inter Immunopharmacol 2001; 1: 329–38CrossRefGoogle Scholar
  59. 59.
    Byrnes-Blake KA, Laurenzana EM, Carroll FI, et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 2003; 461: 119–28PubMedCrossRefGoogle Scholar
  60. 60.
    Gentry WB, Laurenzana EM, Williams DK, et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Inter Immunopharmacol 2006; 6: 968–77CrossRefGoogle Scholar
  61. 61.
    DaNicls JR, Wessinger WD, Hardwick WC, et al. Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology 2006; 185: 36–44CrossRefGoogle Scholar
  62. 62.
    Laurenzana EM, Byrenes-Blake KA, Milesi-Hallé A, et al. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amthatamine disposition in rats. Drug Metab Dispos 2003; 31: 1320–6PubMedCrossRefGoogle Scholar
  63. 63.
    McMillan DE, Hardwick WC, Li M, et al. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther 2004; 309: 1248–55PubMedCrossRefGoogle Scholar
  64. 64.
    Hardin JS, Wessinger WD, Wenger GR, et al. A single dose of monoclonal anti-phencyclidine lgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 2002; 302: 119–26PubMedCrossRefGoogle Scholar
  65. 65.
    Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 2000; 292: 831–7PubMedGoogle Scholar
  66. 66.
    Nabi Pharmaceuticals announces positive results of phase IIb trial of Nic VAX. Press release: 2007 May 2 [online]. Available from URL: http://www.nabi.com/pipeline/publications.php?.id=3 [Accessed 2007 Jun 25]
  67. 67.
    Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78(5): 456–67PubMedCrossRefGoogle Scholar
  68. 68.
    Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 2005; 35: 2031–40PubMedCrossRefGoogle Scholar
  69. 69.
    CYT002-NicQb: a novel vaccine for nicotine addiction. 2006 Jun [press release; online]. Available from URL: http://www.cytos.com/doc/nicQb_June06_E_fv.pdf [Accessed 2007 Jun 6]
  70. 70.
    Keyler DE, Dufek MB, Calvin AD, et al. Reduced nicotine distribution from mother to fetal brain in rats vaccinated against nicotine: time course and influence of nicotine dosing regimen. Bichem Pharmacol 2005; 69(9): 1385–95CrossRefGoogle Scholar
  71. 71.
    Keyler DE, Roiko SA, Benlhabib E, et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 2005; 33: 1056–61PubMedCrossRefGoogle Scholar
  72. 72.
    Pentel PR, Dufek MB, Roiko SA, et al. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. J Pharmacold Exp Ther 2006; 317: 660–6CrossRefGoogle Scholar
  73. 73.
    Harwood HJ, Myers TG, editors. New treatments for addiction: behavioral, ethical, legal, and social questions. Committee on Immunotherapies and Sustained-Released Formulation for Treatment Drug Addiction, National Research Council. Washington, DC: The National Academies Press, 2004Google Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Ahmed Elkashef
    • 1
  • Jamie Biswas
    • 1
  • Jane B. Acri
    • 1
  • Frank Vocci
    • 1
  1. 1.Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC)National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)BethesdaUSA

Personalised recommendations